(A). BMDMs were treated with Vehicle Control or AZD1480 (0.25 μM) for 2 h, stimulated with medium (-) or IFN-γ (10 ng/ml) for up to 4 h, then cell lysates were subjected to immunoblotting with the indicated antibodies. (B). BMDMs were treated with Vehicle Control or AZD1480 (0.25 and 0.5 μM) for 2 h, stimulated with medium (-) or GM-CSF (10 ng/ml) for 30 min, then cell lysates were subjected to immunoblotting with the indicated antibodies. (C). BMDMs were treated with Vehicle or AZD1480 (0.25 μM) for 2 h, and stimulated with medium (-) or IL-6 (10 ng/ml) plus sIL-6R (25 ng/ml) for up to 4 h. Cell lysates were subjected to immunoblotting with the indicated antibodies. (D). BMDMs were treated with Vehicle Control or AZD1480 (0.25 μM) for 2 h, stimulated with medium (-) or LPS (10 ng/ml) for up to 4 h, then cell lysates were subjected to immunoblotting with the indicated antibodies. (E). BMDMs were treated with Vehicle Control or AZD1480 (0.25 μM) for 2 h, stimulated with medium (UN) or LPS (10 ng/ml) plus IFN-γ (10 ng/ml) for 24 h, and nitrite production was measured by Griess. (F). BMDMs were treated with Vehicle Control or AZD1480 (0.25 and 0.5 μM) for 2 h, stimulated with medium (UN) or IFN-γ (10 ng/ml) for 24 h, then MHC Class II expression analyzed by flow cytometry. DCs were treated with Vehicle Control or AZD1480 (0.25 and 0.5 μM) for 2 h, stimulated with medium (UN) or IFN-γ (10 ng/ml) for 24 h, then MHC Class II (G) and CD40 (H) expression was analyzed by flow cytometry. **p<0.001.